Frovatriptan: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
'''''For patient information about Frovatriptan, click [[Frovatriptan (patient information)|here]]''''' | '''''For patient information about Frovatriptan, click [[Frovatriptan (patient information)|here]].''''' | ||
{{SB}} FROVA<sup>®</sup> | {{SB}} FROVA<sup>®</sup> | ||
Revision as of 22:32, 9 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Frovatriptan, click here.
Synonyms / Brand Names: FROVA®
Overview
Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraineheadaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America andMenarini in Europe.[1]
Category
Antimigraine Drugs, Triptans
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Frovatriptan binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of FROVA is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
References